102例儿童肝母细胞瘤的治疗及预后分析  

Analysis on the treatment and prognosis of 102 children with hepatoblastoma

作　　者：张伟令[1] 张谊[1] 黄东生[1] 陈丽萍[1] 易优[1] 张品伟[1] 刘爱萍[1] 支天[1] 

机构地区：[1]首都医科大学附属北京同仁医院儿科,北京100176

出　　处：《中国小儿血液与肿瘤杂志》2015年第6期289-292,共4页Journal of China Pediatric Blood and Cancer

基　　金：首都卫生发展科研专项项目(青年项目;基金编号:2014-4-2054)

摘　　要：目的分析儿童肝母细胞瘤（HB）手术结合化疗的疗效及预后,了解风险因素对预后的影响。方法 2006年9月-2014年6月北京同仁医院收治HB患儿102例。男55例,女47例。通过分析临床资料,研究HB的临床疗效及预后。结果 102例患儿经综合治疗后完全缓解（CR）52例占51.0%,部分缓解（PR）20例占19.6%,死亡28例占27.4%,进展2例（2.0%）。随访至2015年1月1日,平均随访时间27.54±19.95个月,2年总生存率（0S）76.5%,3年无事件生存（EFS）60.5%。对随访时间超过12个月的81例患儿进行Kaplan-Meier生存分析,5年平均生存时间71.1个月,95%可信区间61.2-80.9个月。结论儿童HB经规律化疗结合手术治疗后疗效肯定,但应对PLT、反复复发以及远处转移病例加强随访预防复发。Objective Study on clinical efficacy and prognosis of surgery and chemotherapy for children with hepatoblastoma,and analysis on the affect of risk factors for prognosis.Methods 102 cases of hepatoblastoma were employed from September,2006 through June,2014.Male 55 cases,female 47 cases.Clinical efficacy and prognosis were studied by statistical analysis of clinical data.Results In 102 cases,52 reached complete remission（CR,51%）,and 20 cases got partial remission（PR,19.6%）,and 28 cases died of complications and disease progression（27.4%）.Based on（27.54 ± 19.95） months follow up studies,76.54%patients got 2 year overall survival,and 60.5%patients got 3 years EFS.In 81 cases,5-year average survival time was 71.1 months,and 95%credible interval was 61.2-80.9 months by analysis on kaplan-meier.Conclusions The clinical efficacy was improved with regular chemotherapy combined with surgery for childhood hepatoblastoma.recurrence prevention is important for getting longer EFS.

关 键 词：肝母细胞瘤 儿童 化疗 预后 PLT 

分 类 号：R735.7[医药卫生—肿瘤]